In this review, some of the many abstracts on research into lupus nephritis presented at ACR Convergence 2025 are being highlighted. The abstracts selected demonstrate the advances made on the early recognition of the condition, as well as offering some hope in terms of achieving better outcomes.
Dr. Langford’s final column reflects on 2025’s advocacy, challenges & member teamwork. Click through to read the outgoing ACR president’s parting thoughts.
At this ACR Convergence 2025 session, experts discussed the importance of vaccinating immunocompromised patients with non-live vaccines.
Experts addressed considerations for how to aid patients with juvenile idiopathic arthritis (JIA) in their transition to adult care, specifically highlighting clinical pearls for those with pediatric uveitis and TMJ arthritis.
Experts discuss high-intensity interval training as an underused “disease-modifying drug” for inflammatory diseases. Learn how to safely integrate it into patient treatment plans.
CPPD diagnosis is difficult & treatments are limited. Experts review radiology challenges, off-label options like colchicine, & emerging biologics.
Richard F. Loeser, Jr., MD, MACR, delivering the Oscar Gluck Memorial Lecture at ACR Convergence 2025, discussed research into new treatments for osteoarthritis.
Why do lymphatics fail in inflammatory arthritis? Research from ACR Convergence 2025 points to a network of telocytes & mast cells that control synovial drainage.
At ACR Convergence 2025, Joan T. Merrill, MD, overviewed the current research landscape of chimeric antigen receptor (CAR) T cell therapies for systemic lupus erythematosus (SLE), raising important scientific questions about these emerging treatments.
At this ACR Convergence 2025 session, immunologist Dusan Bogunovic, PhD, discussed his team’s research into how genetic immune diseases manifest with different phenotypes in different people.